Ukraine,
March 2012
This report offers companies, investors, policymakers, and stakeholders crucial insight into the ecosystem of pharmaceutical companies in Ukraine, based on in-depth interviews conducted with leaders and pioneers across the value chain, from government representatives, the international organizations now in charge of Ukraine’s public procurement, country managers of the leading MNCs that have remained in Ukraine, as well as representatives from local SMEs and service providers.
Geopolitical and military strife has beset Ukraine in recent years, followed by a deep economic crisis. Although conflicts are not totally resolved in all corners of the country, a new era of economic growth and possibility seems to be around the corner, with healthcare and the life sciences at its forefront.
This report offers companies, investors, policymakers, and stakeholders crucial insight into the ecosystem of pharmaceutical companies in Ukraine, based on in-depth interviews conducted with leaders and pioneers across the value chain, from government representatives, the international organizations now in charge of Ukraine’s public procurement, country managers of the leading MNCs that have remained in Ukraine, as well as representatives from local SMEs and service providers.
Geopolitical and military strife has beset Ukraine in recent years, followed by a deep economic crisis. Although conflicts are not totally resolved in all corners of the country, a new era of economic growth and possibility seems to be around the corner, with healthcare and the life sciences at its forefront.
